Impact of Interruptions in Chemotherapy on Survival for Patients With Metastatic or Recurrent Cervical Cancer
Intercycle delays during first-line systemic chemotherapy for metastatic or recurrent cervical cancer do not have an adverse effect on survival.
Authors
- April Gorman (ORCID: https://orcid.org/0009-0003-8062-893X)
- Steven Blaine Holloway (ORCID: https://orcid.org/0000-0003-3543-3896)
- Jayanthi Lea (ORCID: https://orcid.org/0000-0002-8657-4309)
- David Scott Miller (ORCID: https://orcid.org/0000-0002-8215-5887)
- Risha Sinha (ORCID: https://orcid.org/0000-0001-7505-4837)
- Arianna Portmann-Baracco (ORCID: https://orcid.org/0000-0003-3489-3751)
- Eileen M. Stock (ORCID: https://orcid.org/0000-0003-2620-5744)
Institutions
- Gynecologic Oncology Group (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1097/coc.0000000000001279
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00